SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing ...

CSIR NET Application Form 2025 Out: The National Testing Agency (NTA) has issued the official notification for the CSIR UGC NET December 2025 Exam. Candidates aspiring for Junior Research Fellowship ...

Prosecutors earlier said they couldn't establish probable cause to charge Comey Former FBI Director James Comey was indicted Thursday on charges of making a false statement and obstruction related to ...

This clears the way for Remulla as Ombudsman applicants like him are required to submit a clearance. Failure to do so may cause their disqualification. MANILA, Philippines – Department of Justice ...

An FBI agent accused of misconduct in connection with the investigation of Jan. 6 defendants has regained his security clearance and received back pay as part of a settlement with the bureau. Marcus ...

CAMBRIDGE, Mass., Sept. 9, 2025 /PRNewswire/ -- ARTBIO, Inc. ("ARTBIO"), a clinical-stage radiopharmaceutical company developing a new class of Pb212 alpha radioligand therapies (ARTs), today ...

Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of ...

NEW TAIPEI CITY, July 28, 2025 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919) today announced that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with SUPREME-01 ...

CINCINNATI (WKRC) - A program inviting teens to learn about the Federal Bureau of Investigation will return to Cincinnati, Dayton and Columbus in July. FBI Cincinnati's Teen Academy will take place ...

The FBI has reported a significant decline in one of the nation’s most devastating forms of violence. According to the 2024 Active Shooter Incidents in the United States report, released Tuesday, the ...

(RTTNews) - Erasca, Inc. (ERAS) announced clearance of an investigational new drug application by the FDA for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the ...